Ticker

Highlights The Precision Peptide Company's newly launched direct-to-consumer and telehealth platform is now available in all 50 states of the United States. 100% U.S.-compounded peptide products are supported through a 503A compounding agreement July 23, 2026 is the scheduled FDA advisory committee review date for several peptide substances, including BPC-157; The Precision Peptide Company's compounding, telehealth,…

Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that further to its news release dated June 11, 2026, it has closed its previously announced non-brokered private placement of common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share under the Listed Issuer Financing…

Highlights Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate Patches are manufactured and independently tested in the United States Marks the Company's transition from testing to commercialization Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) -…

HighlightsThe Precision Peptide Company can now sell its peptide products directly to consumers online across all 50 U.S. states, with

Highlights